Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
about
Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adultsAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementThe role of galenic innovation in improving treatment compliance and persistence: three case studies.High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case reportThe art of prescribing pharmacological management of adult ADHD: implications for psychiatric care.Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.Attention deficit hyperactivity disorder in adulthood: diagnosis, etiology and therapyOROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.Does extended release methylphenidate help adults with hoarding disorder?: a case series.Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder.Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?Adherence to stimulants in adult ADHD.Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD.
P2860
Q26858868-6CAFA681-4322-4828-8845-203043CEED04Q28295525-3FAD1331-67E8-491F-9D02-6591AAB7226AQ35454381-2B592194-33A2-4334-A26E-1CDFF199DFADQ36125316-57129114-AAA8-4C39-969A-75461801A9D7Q37199280-D7999DAD-2F50-4E11-8D6E-64AC334A9F54Q37318744-276899DF-6C52-43CF-8322-EED98C1A6463Q37560640-B82FBB30-BF91-4E5D-9BD6-C36E49F088C4Q37578475-CA8EF1B9-3141-421F-9E79-407BC87BB583Q37730960-01FCA852-6BB4-4C62-B2CB-A6C846954CC6Q37893536-CC3C7122-936A-4161-9E62-1FDF20605CF2Q39621300-A90D6C82-428B-4832-B7C9-AE0FB6E44F02Q42113942-FC62AADE-6AEA-44EA-9FC0-62F111605E73Q48083751-DB6B1707-6BF7-4C8E-8511-390F2F4FCE8BQ49083889-E100EA1E-4A02-4345-881D-139F3D826437Q50780419-0B8E5469-51EA-4895-82AA-E1AEAE75DDA8
P2860
Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@ast
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@en
Comparative acute efficacy and ...... eficit/hyperactivity disorder.
@nl
type
label
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@ast
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@en
Comparative acute efficacy and ...... eficit/hyperactivity disorder.
@nl
prefLabel
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@ast
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@en
Comparative acute efficacy and ...... eficit/hyperactivity disorder.
@nl
P2093
P2860
P356
P1433
P1476
Comparative acute efficacy and ...... deficit/hyperactivity disorder
@en
P2093
Craig Surman
Evan Michel
Jessica Martin
Paul Hammerness
Robert Doyle
Thomas J Spencer
P2860
P2888
P356
10.1186/1471-244X-7-49
P577
2007-09-14T00:00:00Z
P5875
P6179
1017912672